| 英文名称 |
中文名称 |
CAS |
|
Ritlecitinib Intermediates
|
利特昔替尼中间体 |
1207947-49-6 |
|
Allisartan Isoproxil
|
阿利沙坦酯 |
947331-05-7 |
|
Imrecoxib
|
艾瑞昔布 |
395683-14-4 |
|
Carbamic acid, N-[5-[(4-methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-2-yl]-, ethyl ester
|
乌帕替尼中间体 |
1869118-24-0 |
|
Pimavanserin Intermediates
|
匹莫范色林酒石酸盐中间体 |
1837794-51-0 |
|
Ritlecitinib Intermediates
|
利特昔替尼中间体 |
2922238-87-5 |
|
(2-Butyl-5-nitro-3-benzofuranyl)[4-[3-(dibutylamino)propoxy]phenyl]methanone
|
盐酸决奈达隆中间体 |
141645-23-0 |
|
Etrasimod Intermediates
|
依曲莫德精氨酸中间体 |
957208-65-0 |
|
4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
|
非奈利酮中间体 |
1050477-27-4 |
|
N-[5-[(4-Methylphenyl)sulfonyl]-5H-pyrrolo[2,3-b]pyrazin-2-yl]carbamic acid 1,1-dimethylethyl ester
|
乌帕替尼中间体 |
1201187-44-1 |
|
4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid
|
非奈利酮中间体 |
1050477-45-6 |
|
3-Pyridazinecarboxylic acid, 4,6-dichloro-, lithium salt, hydrate (1:1:1)
|
氘可来昔替尼中间体 |
2245111-15-1 |
|
Azilsartan
|
阿奇沙坦酯钾盐中间体 |
147403-03-0 |
|
Ritlecitinib Tosylate
|
利特昔替尼对甲苯磺酸盐 |
2192215-81-7 |
|
6-CHLORO-3-(1-METHYLETHYL)-2,4-(1H,3H)-PYRIMIDINEDIONE
|
玛伐凯泰中间体 |
887581-47-7 |
|
2,2,14,14-tetramethyl-8-oxopentadecanedioic acid
|
贝派度酸中间体 |
413624-71-2 |
|
Bempedoic Acid Intermediates
|
贝派度酸中间体 |
123469-92-1 |
|
ritlecitinib
|
利特昔替尼 |
1792180-81-4 |
|
Ritlecitinib Intermediates
|
利特昔替尼中间体 |
1227917-63-6 |
|
Mavacamten
|
玛伐凯泰 |
1642288-47-8 |
|
Heptanoic acid, 7-chloro-2,2-dimethyl-, ethyl ester
|
贝派度酸中间体 |
2570179-39-2 |
|
Ritlecitinib Intermediates
|
利特昔替尼中间体 |
2295746-50-6 |
|
N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
|
枸橼酸托法替布中间体 |
477600-74-1 |
|
Upadacitinib
|
乌帕替尼（半水合物） |
2050057-56-0 |
|
Unii-na83F1sjsr
|
匹莫范色林酒石酸盐 |
706782-28-7 |
|
Azilsartan Medoxomil
|
阿齐沙坦酯钾盐中间体 |
863031-21-4 |
|
7,8-difluoro-6,11-dihydro-Dibenzo[b,e]thiepin-11-ol
|
巴洛沙韦中间体 |
1985607-83-7 |
|
Etrasimod Arginine
|
依曲莫德精氨酸 |
1206123-97-8 |
|
Avatrombopag maleate
|
马来酸阿伐曲泊帕 |
677007-74-8 |
|
2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate
|
非奈利酮中间体 |
1050477-43-4 |
|
N-((3R,6S)-6-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
|
利特昔替尼中间体 |
2042650-70-2 |
|
Butylphthalide
|
丁苯酞 |
6066-49-5 |
|
(Z)-2-cyanoethyl 2-(4-cyano-2-methoxybenzylidene)-3-oxobutanoate
|
非奈利酮中间体 |
1050477-39-8 |
|
Upadacitinib
|
乌帕替尼（无水物） |
1310726-60-3 |
|
Lobeglitazonesulfate
|
洛贝格列酮硫酸盐 |
763108-62-9 |
|
Tofacitinib Intermediates
|
枸橼酸托法替布中间体 |
477600-73-0 |
|
Ritlecitinib Intermediates
|
利特昔替尼中间体 |
1207853-23-3 |
|
Baloxavir Marboxil
|
玛巴洛沙韦 |
1985606-14-1 |
|
DRONEDARONE HYDROCHLORIDE
|
盐酸决奈达隆 |
141625-93-6 |
|
Bicyclol
|
双环醇 |
118159-48-1 |
|
Finerenone
|
非奈利酮 |
1050477-31-0 |
|
BempedoicAcid
|
贝派度酸 |
738606-46-7 |
|
2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxylate
|
非奈利酮中间体 |
1050477-44-5 |
|
Etrasimod Intermediates
|
依曲莫德精氨酸中间体 |
1206124-34-6 |
|
Deucravacitinib
|
德卡伐替尼 |
1609392-27-9 |
|
Bicyclol Intermediates
|
双环醇中间体 |
105868-34-6 |
|
Bicyclol Intermediates
|
双环醇中间体 |
211996-66-6 |
|
ABT-494 intermediate
|
乌帕替尼中间体 |
1428243-24-6 |
|
Avatrombopag Impurity 22
|
马来酸阿伐曲泊帕中间体 |
570403-14-4 |
|
Iguratimod
|
艾拉莫德 |
123663-49-0 |
|
Tofacitinib Citrate
|
枸橼酸托法替布 |
540737-29-9 |
|
Azilsartan kaMedoxoMil
|
阿齐沙坦酯钾盐；美阿沙坦钾 |
863031-24-7 |
|
(3R,4S)-3-(2-Bromoacetyl)-4-ethyl-1-pyrrolidinecarboxylic acid phenylmethyl ester
|
乌帕替尼中间体 |
1428243-26-8 |
|
7,8-difluorodibenzo[b,e]thiepin-11(6H)-one
|
巴洛沙韦中间体 |
2136287-66-4 |
|
Etrasimod Intermediates
|
依曲莫德精氨酸中间体 |
1206124-13-1 |
|
(12aR)-3,4,12,12a-Tetrahydro-7-(phenylmethoxy)- 1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione
|
巴洛沙韦中间体 |
1985607-70-2 |
|
Betahistine mesylate
|
甲磺酸倍他司汀 |
54856-23-4 |
